Status:
COMPLETED
Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules
Lead Sponsor:
Maria Sklodowska-Curie National Research Institute of Oncology
Conditions:
Thyroid Nodule
Thyroid Neoplasm
Eligibility:
All Genders
18+ years
Brief Summary
This study evaluates the usefulness of molecular classifier to aid the diagnosis of malignancy in the material obtained by fine-needle aspiration biopsy (FNAB) of thyroid nodule. All participants will...
Detailed Description
Currently, the diagnosis of malignancy of thyroid nodule is based on cytological assessment of fine-needle aspiration biopsy (FNAB) classified according to the Bethesda System for Reporting of Thyroid...
Eligibility Criteria
Inclusion
- a diagnosis of thyroid nodule
- considerable chance for surgical procedure following biopsy result
- patient's consent for collection of material during routine fine needle aspiration biopsy
Exclusion
- age below 18 years
- the presence of contraindications that make surgical treatment impossible
- prior diagnosis of thyroid cancer
- antithrombotic treatment except of acetylsalicylic acid or low molecular weight heparin at a prophylactic dose
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
599 Patients enrolled
Trial Details
Trial ID
NCT03392402
Start Date
January 1 2017
End Date
December 31 2020
Last Update
September 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
Gliwice, Poland, 44-101